Ovarian cancer is the most common cause of death from gynecologic cancers in the Western world. It is estimated that in 1996 about 27 000 new cases of ovarian cancer were diagnosed and nearly 15 000 deaths occurred in the United States due to this disease (1, 2) . The current treatment of ovarian cancer is based on debulking surgery combined with chemotherapy (3) (4) (5) (6) (7) . Various antineoplastic agents, such as cisplatin, cyclophosphamide, paclitaxel (Taxol), or doxorubicin are being used for chemotherapy, mostly in combination regimens (3) (4) (5) (6) (7) . However, long-term outcome of such therapies is disappointing and prolonged use of cytotoxic agents is associated with toxic effects.
A modern approach to reducing the toxicity is the targeting of cytotoxic agents directly to cancerous cells. The presence of specific binding sites for peptide hormones on tumor cells renders these peptides appropriate for use as carriers that can be conjugated with cytotoxic radicals. Receptors for luteinizing hormone-releasing hormone (LH-RH) have been found on ovarian, endometrial, breast, and prostate cancers. Approximately 80% of human epithelial ovarian cancer specimens have been found to be LH-RH receptor positive (3, 4) . In the past decade, several prototypes of cytotoxic analogues of LH-RH have been synthesized in our laboratory (8) (9) (10) . These hybrids consisted of LH-RH agonists or antagonists linked to various cytotoxic agents (8) (9) (10) . Recently, we developed a cytotoxic LH-RH analogue containing doxorubicin (AN-152), which fully retains cytotoxic activity of the radical and receptor binding affinity of the peptide carrier (11) . In this study, we have evaluated the effects of AN-152 on the growth of OV-1063 human epithelial ovarian cancers (12) that have high-affinity receptors for LH-RH (13) . We also tested AN-152 on UCI-107 human epithelial ovarian cancers (14, 15) , which have been found to be negative for the presence of the LH-RH receptor.
Materials and Methods

Chemicals
Agonistic analogue [D-lysine 6 ]LH-RH (pyroGluHis-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-NH 2 ) used as a carrier was synthesized in our laboratory by solid-phase method (8) . Cytotoxic LH-RH conjugate (AN-152) was made in our laboratory by coupling one molecule of doxorubicin-14-Ohemiglutarate to the -amino group of the D-lysine side chain of the carrier and purified by highperformance liquid chromatography (HPLC) as described previously (11) . The approximate half-life of AN-152 in the serum of nude mice at 37°C was 10 minutes as based on HPLC measurements. The compounds were dissolved in 0.9% sodium chloride and injected intraperitoneally.
Animals
Female athymic (nude) mice (Ncr nu/nu), 5 or 6 weeks old on arrival, were obtained from the National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD). The mice were housed in sterile cages under laminar air flow hoods in a temperature-controlled room with a 12-hour light/12-hour dark schedule and were fed autoclaved chow and water ad libitum.
All experiments were performed according to institutional ethical guidelines. Tumor cells were transplanted into the mice in our laboratory.
Cells and Tumors
Human epithelial ovarian cancer cell line OV-1063 was obtained from American Type Culture Collection (Rockville, MD). This cell line originated from a metastatic papillary cystadenocarcinoma of the ovary in a 57-year-old woman and is positive for carcinoembryonic antigen (12) . It was maintained in RPMI-1640 medium, supplemented with 10% fetal bovine serum (13), 1 mM pyruvate, and 1:100 minimal essential medium vitamins, 2 mM glutamine, penicillin (100 U/mL), streptomycin (100 g/mL), and amphotericin B (0.25 g/mL) (all from Life Technologies, Inc. [GIBCO BRL]; Grand Island, NY). Cells were cultured in T-75 flasks (Corning Costar Corp., Cambridge, MA) in a humidified atmosphere of 5% CO 2 and 95% air at 37°C and passed every 4-6 days using 0.25% trypsin-EDTA. The UCI-107 epithelial ovarian cancer cell line was provided by Dr. A. Manetta (University of California, Irvine Medical Center, Orange). UCI-107 originated from a patient with papillary adenocarcinoma of the ovary (14, 15) . It was maintained in the culture media cited above.
In Vivo Studies
Xenografts were initiated by subcutaneous injection of 1 × 10 7 OV-1063 cells or UCI-107 cells into the right flank of four nude mice (13) . Tumors resulting after 4 weeks were aseptically dissected and mechanically minced; 1-mm 3 tumor pieces were transplanted subcutaneously by trocar needle into the right flank of the mice. The tumor take rate was nearly 90%. One week after tumor transplantation, when the tumors measured about 15-25 mm 3 , the mice were assigned to experimental groups of eight to 10 animals each and the therapy was initiated. The concentration of LH-RH receptors on OV-1063 tumors grown in nude mice was similar to that found on human epithelial ovarian cancer specimens.
In experiment 1, mice with OV-1063 tumors were divided into six groups of nine animals each, which received the following treatments as single intraperitoneal injections: group 1, saline (control); group 2, AN-152 at a dose of 700 nmol/20 g; group 3, AN-152 at a dose of 413 nmol/20 g; group 4, doxorubicin at a dose of 413 nmol/20 g (12 mg /kg), which corresponds to maximum tolerated dose ( In experiment 2, mice with OV-1063 tumors were divided into four groups and were given intraperitoneal injections as follows: group 1 (control, 10 animals) received saline; group 2 (nine animals) received AN-152 at a dose of 413 nmol/20 g twice (days 1 and 10); group 3 (nine animals) received AN-152 at a dose of 600 nmol/20 g as a single injection; and group 4 (eight animals) received doxorubicin at a dose of 413 nmol/20 g twice (days 1 and 10).
In the third experiment, UCI-107 tumors were used and the mice were divided into three groups that received the following treatment as a single intraperitoneal injection: group 1 (control, nine animals) received saline; group 2 (nine animals) received AN-152 at a dose of 413 nmol/20 g; and group 3 (eight animals) received doxorubicin at a dose of 413 nmol/20 g. Tumors were measured once or twice a week with microcalipers, and tumor volume was calculated using the following formula; length × width × height × 0.5236 (16) . Measurement of tumor growth was continued for 4 weeks. The percent change in tumor volume from the start of the treatment was used as a parameter of a growth rate. Tumor doubling time was calculated between the start of the treatment and the end of the experiment. After 4 weeks, the mice were killed under light methoxyflurane anesthesia according to institutional standards. Trunk blood was collected and centrifuged at 1000g for 30 minutes at 4°C and serum was stored at −20°C until assayed. Tumor, liver, heart, uterus, and ovary were carefully removed, cleaned, and weighed. Tumor burden at the end of the experiment was calculated as tumor weight (mg)/body weight (g). Samples of tumor tissue were fixed in 10% buffered neutral formalin for histologic examination. Tumor pieces were also stored at −80°C for receptor studies and molecular biology analysis.
Pathologic Procedure
Samples of tumor tissue were fixed in 10% buffered formalin. Specimens were embedded in Paraplast (Oxford Labware, St. Louis , MO). Sections (6 m thick) were cut and stained with hematoxylineosin. Mitotic and apoptotic cells were counted in 10 standard high power microscopic fields containing on the average 300 cells, and their number per 1000 cells was accepted as the mitotic and apoptotic indices, respectively. For demonstration of the nucleolar organizer region (NOR) in tumor cell nuclei, the argyrophilic NOR (AgNOR) method of Chiu et al. (17) was used with slight modifications (18) . Nucleolar organizer regions are sites of genes that encode for ribosomal RNA. They are associated with argyrophilic nonhistone acidic proteins that can be detected by the AgNOR method. The silverstained black dots in 50 cells of each tumor were counted, and the AgNOR number per cell was calculated.
Determination of Serum LH Levels
In experiment 1, blood samples taken from mice at the end of treatment period of 4 weeks were tested for serum LH levels by use of a specific radioimmunoassay (RIA). The antibodies used for the RIA (i.e., rat LH-RP-3/AFP-7187B/, rat LH-I-9/AFP-10250C/, and anti-rat LH-RIA-S-11/AFP-C 697071P) were provided by the National Hormone and Pituitary Program (Rockville, MD).
Receptor Assay
Receptors for LH-RH and EGF on OV-1063 and UCI-107 tumors were measured by ligand competition assays at the end of experiments 1, 2, and 3. Preparation of tumor membrane fractions and receptor-binding studies of LH-RH and EGF were performed as previously described (19, 20) .
[D-Trp 6 ]LH-RH was radioiodinated by the chloramine-T method in our laboratory (19) 
Isolation of Messenger RNA (mRNA)
Total RNA was extracted from frozen tissue samples by using RNAzol B (TEL-TEST Inc., Friendswood, TX) according to the manufacturer's instructions. The RNA pellets were suspended in 100 L of 10 mM Tris, 1 mM EDTA buffer (pH 8.0), and quantified spectrophotometrically. The optical density ratios (260 nm/280 nm) of the RNA preparations were greater than 1.8.
Reverse Transcription (RT)
One microgram of total RNA was used in a test tube containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 5 mM MgCl 2 , 1 mM of each deoxynucleoside triphosphate, 1 U RNase inhibitor, and 2.5 M random hexamer primers in a final volume of 19 L of RNase-free deionized distilled water. The mixture was heated for 10 minutes at 65°C, quenched on ice, then 2.5 U of Moloney murine leukemia virus reverse transcriptase (The Perkin-Elmer Corp., Norwalk, CT) in 1 L was added, for a total reaction volume of 20 L. The mixture was incubated at room temperature for 10 minutes and then at 42°C for 1 hour. The reaction was ended by heating at 95°C for 5 minutes and quenching on ice.
Polymerase Chain Reaction Amplification
The 20-L solutions of the RT reaction from each sample were diluted into a final volume of 100 L by a mixture of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, and 2 mM MgCl 2 . Fifty picomoles of each primer and 2.5 U Amplitaq DNA polymerase (The Perkin-Elmer Corp.) were also added. In the first experiment using reverse transcription-polymerase chain reaction (RT-PCR), the sense and antisense primers for LH-RH receptors were 5Ј-GACCTT-GTCTGGAAAGATCC-3Ј and 5Ј-CAGGCTGAT-CACCACCATCA-3Ј, respectively. These primers yield a 319-base-pair (bp) fragment that is complementary to nucleotide positions 93-411 in human LH-RH receptor complementary DNA (cDNA). The primers for EGF receptor were 5Ј-CTACCAC-CACTCTTTGAACTGGACCAAGG-3Ј (sense) and 5Ј-TCTATGCTCTCTCACCCCGTTCCAAG-TATCG-3Ј (antisense). These primers yield a 675-bp fragment that is complementary to nucleotides at positions 1488-2162 in human EGF receptor cDNA. The sense and antisense primers for ␤-actin used for internal control were 5Ј-ATCTGGCACCA-CACCTTCTACAATGAGCTGCG-3Ј and 5Ј-C G T C A T A C T C C T G C T T G C T G A T C C A -CATCTGC-3Ј, respectively. These primers yield a 838-bp fragment (nucleotides 294-1131). These PCR oligonucleotide primers were synthesized by use of the model 394 DNA/RNA synthesizer (Applied Biosystems, Foster City, CA). PCR was started after an initial denaturation step at 95°C for 3 minutes by the addition of 2.5 U Amplitaq (The PerkinElmer Corp.), followed by 40 cycles of replication (1 minute at 94°C, 1 minute at 54°C, and 1 minute at 72°C), and the final extension was done for 7 minutes at 72°C using a Stratagene Robocycler 40 system (Stratagene, La Jolla, CA ).
The second experiment was done to investigate the expression of mRNA for EGF receptors. The primers used for human EGF (hEGF) receptor were sense 5Ј-ACGCAGATAGTCGC-CCAAAGTTCC-3Ј (nucleotides 3047-3070) and antisense 5Ј-AGGAAGGTGTCGTCTATGCT-GTCC-3Ј (nucleotides 3423-3446). The primers for human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) used for another internal control were sense 5Ј-TCCTCTGACTTCAACAGCGACACC-3Ј (nucleotides 907-930) and antisense 5Ј-TCTCTC-TTCCTCTTGTGCTCTTGG-3Ј (nucleotides 1091-1114). Twenty-three cycles of PCR for hEGF receptor and for hGAPDH were carried out under the same conditions as in the first experiment. The number of cycles was previously determined to be within the exponential range of PCR product amplification necessary for quantitative densitometry. Negative controls were run in parallel to check for DNA contamination of samples. Ten microliters of the final PCR product was electrophoresed in a 1.8% agarose gel. Bands were visualized on an ultraviolet transilluminator following ethidium bromide staining.
Southern Blot Analysis
The gel was soaked in denaturation buffer containing 50 mM NaOH and 1.5 M NaCl and then in neutralization buffer containing Tris-HCl (pH 8.0) and 1.5 M NaCl. The gel was then blotted onto a nylon membrane (Hybond N + , Amersham Life Science Inc.) by capillary transfer, and the DNA was linked to the membrane by heating for 2 hours at 80°C. Sample blots were prehybridized at 60°C for 16 hours in a buffer containing 4× standard saline citrate (SSC), 2× Denhardt's solution, 0.1% sodium dodecyl sulfate (SDS), 5 mM EDTA, and 100 g/ mL denatured salmon sperm DNA. After prehybridization, the sample blots were hybridized at 60°C for 20 hours in hybridization buffer containing 5× SSC, 0.5× Denhardt's solution, 0.02 M Tris-HCl, 100 g/mL sonicated salmon DNA, and 150 ng of 5Ј( 32 P)-end-labeled oligonucleotide probe. The oligonucleotide probe used for hEGF receptor was 5Ј-TGGATGAAGAAGACATGGACGACGTG-GTGG-3 (nucleotides 3191-3220) and for hGAPDH was 5Ј-TGTCAAGCTCATTTCCTGGTCT-GACAACGA-3Ј (nucleotides 981-1010). Probes were labeled in a reaction mixture containing 70 Ci 
In Vitro Cytotoxicity Assay
The crystal violet assay was performed to determine inhibitory effects in vitro of AN-152 and doxorubicin on proliferation of OV-1063 and UCI-107 ovarian cancer cell lines. This assay is based on quantification of biomass, as described by Bernhardt et al. (22) . Relative cell number in treated and control wells was determined by crystal violet staining and expressed as T/C values where T/C ‫ס‬ (T − C 0 )/(C − C 0 ) × 100 [T ‫ס‬ absorbance of treated cultures, C ‫ס‬ absorbance of control cultures, and C 0 ‫ס‬ absorbance of cultures at the start of incubation (t ‫ס‬ 0)]. The measured absorbance is proportional to the cell number. T/C values obtained at three different concentrations were used to calculate IC 50 values, the drug concentration that inhibited cell growth by 50% compared with untreated control cultures.
Statistical Methods
All data are expressed as the mean ± standard error of the mean, and statistical analyses of the tumor data were performed with use of Student's t test (two-tailed). Differences were considered statistically significant when P<.05.
Results
Effect of AN-152 on the Growth of Human Epithelial Ovarian Cancers OV-1063 and UCI-107 in Nude Mice
In experiment 1, after 2 weeks, the volume of the OV-1063 ovarian cancers in the two groups receiving AN-152 was significantly reduced to 3.9 ± 1.2 mm 3 for the high-dose group (700 nmol/20 g) (P ‫ס‬ .0024) and to 58.2 ± 23.5 mm 3 for the low-dose group (413 nmol/20 g) (P ‫ס‬ .0027) compared with the control group (892.7 ± 224.4 mm 3 ), corresponding to 99% and 93% decreases in tumor volume, respectively (Fig. 1, A) . Treatment with AN-152 for 4 weeks significantly decreased the final tumor volume and tumor weight in the group treated with a high dose to 149.0 ± 96.3 mm 3 (96.3% reduction; P ‫ס‬ .0049) and 94.8 ± 49.2 mg (97% reduction; P ‫ס‬ .0056), respectively, and in the low-dose group to 623.4 ± 273.2 mm 3 (84% reduction; P ‫ס‬ .008) and 480.6 ± 224.4 mg (84% reduction; P ‫ס‬ .0106), respectively. In the control group, tumors measured 3984.8 ± 1053.6 mm 3 and weighed 3016.8 ± 820.2 mg. Tumor doubling time in mice receiving 413 nmol/20 g of AN-152 was significantly (P ‫ס‬ .044) extended to 11.1 ± 3.3 days from 3.8 ± 0.5 days in the control groups. At the end of the experiment, there was no significant difference in body weight in the group treated with the low dose of AN-152 (413 nmol/20 g) compared with the control group and tumor burden was significantly decreased (P ‫ס‬ .016) to 22.8 ± 10.9 mg/g body weight compared with that of control animals (110.5 ± 29.9 mg/g body weight). Tumor burden in mice treated with 700 nmol/20 g of AN-152 was reduced even more to 6.2 ± 3.3 mg/g body weight (P ‫ס‬ .0099), although body weights were decreased to 16.2 ± 0.5 g compared with the control animals (22.8 ± 0.8 g) and two of nine animals died. Mice treated with a mixture of high-dose doxorubicin (700 nmol/20 g) and [D-lysine 6 ]LH-RH were all dead within 5 days after treatment. In the group treated with 413 nmol/20 g doxorubicin, six of nine animals died because of the toxic effects of the drug. Three days after treating nude mice with high-dose AN-152, their white blood cell (WBC) counts were 2640 ± 303/mm 3 of peripheral blood compared with 4820 ± 638/mm 3 in control animals (P ‫ס‬ .015);
if the mice were treated with AN-152 at a dose of 413 nmol/20 g, 3 days later their WBC counts were reduced to 4040 ± 856/ mm 3 (P ‫ס‬ .41). After 7 days, WBC counts were normal in both groups treated with AN-152. In the group that received the high-dose AN-152, weights of the ovary (P ‫ס‬ .0407), heart (P ‫ס‬ .026), and liver (P ‫ס‬ .0029) were significantly decreased.
In experiment 2, performed to find an improved regimen, AN-152 was administered according to two different protocols (Fig. 1, B) . Final tumor volume and tumor weight in the group treated twice with AN-152 at a dose of 413 nmol/20 g decreased to 555.2 ± 215.1 mm 3 (62% reduction; P ‫ס‬ .0488) and 237.3 ± 89.6 mg (71.5% reduction; P ‫ס‬ .0978), respectively. In the group that received a single administration of AN-152 at a dose of 600 nmol/20 g, tumor volume and weight decreased to 382.9 ± 90.3 mm 3 (74.% reduction; P ‫ס‬ .0433) and 194.3 ± 48.7 mg (77% reduction; P ‫ס‬ .0731), respectively, and only one of nine animals died. In the control group, tumors measured 1472.1 ± 456.9 mm 3 and weighed 832.8 ± 311.4 mg. In the group treated twice with doxorubicin at the dose of 413 nmol/20 g, five of eight animals died by day 17 and seven of eight animals were dead by day 35. In the groups treated twice with 413 nmol/20 g AN-152 or once with 600 nmol/20 g, tumor burden was decreased (P ‫ס‬ .062 and P ‫ס‬ .116, respectively) and tumor doubling time was significantly increased (P ‫ס‬ .0377 and P ‫ס‬ .045, respectively). In experiment 2, mice treated with 600 nmol/20 g of AN-152 showed only a 14.6% weight loss and in mice treated twice with 413 nmol/20 g of AN-152, the mean body weight increased by 7.1%.
In experiment 3, neither AN-152 nor doxorubicin at a dose of 413 nmol/20 g demonstrated a statistically significant inhibitory effect on the growth of UCI-107 human epithelial ovarian cancer (Fig.  1, C) . In experiment 1, no significant differences in serum LH levels were observed between the groups and therefore serum LH was not followed in subsequent experiments.
Histologic Findings and Serum LH Levels
Receptor Analysis
In experiments 1 and 2, receptor assays on OV-1063 tumor membranes of control animals showed high-affinity binding sites for EGF (Table 1 ). The number of receptors for EGF was decreased after treatment with AN-152 compared with animals in the control group, although the reduction was not significant in the groups that were treated one time with 413 or 700 nmol/20 g in experiment 1 (Table 1) . In both experiments, specific binding sites for LH-RH were found on OV-1063 tumors of control animals. However, in all groups treated with AN-152, receptors for LH-RH were no longer detectable (Table 1) . In experiment 3, the receptors for LH-RH could not be found in UCI-107 ovarian tumors of control animals.
Molecular Biology Analysis
The mRNAs for LH-RH receptor and for EGF receptor were detected on OV-1063 human epithelial ovarian cancers by use of a RT-PCR assay (Fig. 2, A) . However, the expression of mRNA for LH-RH receptor was not found in UCI-107 human ovarian cancers (Fig. 2, A) . The PCR products of hEGF receptors from OV-1063 tumors in experiment 2, obtained after RT-PCR, were confirmed by Southern blot analysis (Fig. 2, B) . Semiquantitative analysis of the developed bands by densitometry showed that in the group treated twice with AN-152 at a dose of 413 nmol/ 20 g, the level of EGF receptor mRNA expression was decreased to 68.0% ± 17.5% compared with its level of expression in control animals (100% ± 6.5%) (Fig. 3) ; however, the decrease was not statistically significant (P ‫ס‬ .46). In the group treated with AN-152 at a dose of 600 nmol/20 g, the EGF receptor mRNA expression decreased to 56.0% ± 6.8% compared with the control group (P ‫ס‬ .003) (Fig. 3) .
In Vitro Cytotoxicity Assay
The concentrations of AN-152 and doxorubicin that inhibited the proliferation of OV-1063 human ovarian cancer cell line in vitro at 115 hours by 50% (IC 50 ) were 1. 
Discussion
Chemotherapy provides effective treatment for many cancers, but in spite of the development of modern antineoplastic drugs, their peripheral toxicity remains a major problem (1, 10) . Targeted chemotherapy may be more selective and would greatly reduce the side effects of cytotoxic agents. On the basis of the presence of receptors for LH-RH on mammary, ovarian, endometrial, and prostatic tumors, a novel class of antitumor drugs was developed, based on LH-RH analogues linked covalently to various cytotoxic radicals (8) (9) (10) (11) . In one of these hybrid molecules (AN-152) , doxorubicin, which can be cytotoxic by membrane action without entering the cells (23) (24) (25) 6 ]LH-RH. Doxorubicin showed no significant antitumor effect; in fact, at a dose of 413 nmol/20 g, which corresponds to the maximum tolerated dose (27) , most mice died because of the toxic effects of the drug. In experiment 1, the unconjugated mixture of doxorubicin and [D-lysine 6 ] LH-RH at doses of 700 nmol/20 g each, killed all animals within 5 days after treatment, whereas 700 nmol/20 g of AN-152 was much less toxic and produced a statistically significant (P ‫ס‬ .0049) decrease in tumor volume. These results show that the cytotoxic LH-RH conjugate is more effective and less toxic than an equimolar amount of radical alone, carrier alone, or a mixture of radical and carrier. The final reductions in measured tumor volumes were 96% for 700 nmol/20 g and 84% for 413 nmol/20 g of AN-152. Although the dose of 700 nmol/20 g of AN-152 demonstrated an excellent tumor inhibitory effect, it caused a marked weight loss. Doses of 600 nmol/20 g of AN-152 or 413 nmol/20 g of AN-152, given twice, were less toxic and still able to effectively inhibit tumor growth. Among known side effects of doxorubicin is leukopenia (1,7,10,27) , which was observed only in animals treated with AN-152 at a dose of 700 nmol/20 g. Specific receptors for LH-RH and EGF were found on membranes of OV-1063 human epithelial ovarian cancers. After treatment with AN-152, the receptors for LH-RH evanesced and the number of receptors for EGF was reduced. No receptors for LH-RH could be found on UCI-107 human ovarian cancers and AN-152 did not inhibit growth of this tumor. These findings indicate that this cytotoxic analogue might more selectively kill tumor cells expressing LH-RH receptors. The fact that UCI-107 ovarian cancers, which lack receptors for LH-RH, did not respond to AN-152, supports the view that the effects of AN-152 might be exerted, at least in part, directly on the tumors. The inhibition of the growth of OV-1063 ovarian cancer by analogue AN-152 was accompanied by a marked decrease in the number of EGF receptors and in the levels of their mRNA. This observation may be of special relevance. Various studies (28) (29) (30) (31) suggest that EGF is involved in proliferation of human epithelial ovarian cancer. EGF receptor mRNA is expressed in primary human ovarian adenocarcinomas (30) (31) (32) and EGF receptor status has been associated with the biologic aggressiveness and poor survival in patients with ovarian cancer (29, 32) . Previously, we showed that LH-RH antagonist Cetrorelix suppressed the growth of OV-1063 cancers in vivo and decreased EGF receptor protein and mRNA expression (33) . This down-regulation (i.e., decreased expression) of EGF receptors might be responsible for the inhibitory effects of Cetrorelix and cytotoxic analogue AN-152 on ovarian cancers.
Although cytotoxic LH-RH analogues could exert hormonal effects, the predominant mechanism of action in the case of AN-152 appeared to be based on the local cytotoxic and tumoricidal action. Our work supports the view that LH-RH analogues can serve as carriers for chemotherapeutic agents and that such conjugates might deliver cytotoxic radicals more selectively to tumor cells by binding to membrane LH-RH receptors. Our findings suggest the merit of further investigations to determine whether cytotoxic LH-RH analogues could be used for the treatment of advanced ovarian carcinomas that possess receptors for LH-RH. Fig. 3 . Densitometric analysis of epidermal growth factor (EGF) r e c e p t o r m e s s e n g e r R N A (mRNA) from OV-1063 ovarian tumors of control mice and animals treated with AN-152. The levels of EGF receptor mRNA were standardized according to the levels of human glyceraldehyde-3-phosphate dehydrogenase mRNA and are expressed as a percentage of the control value. The results are presented as mean values ± standard error of the mean. * ‫ס‬ P ‫ס‬ .46 and ** ‫ס‬ P ‫ס‬ .003, both determined by use of the Student's t test (twotailed).
